DEAL/TRANSACTION: CSL limited had agreed to buy Novartis AG’s global influenza vaccine business for $275 million, part of the Swiss drugmaker’s drive to focus on its best assets. The business will be...
CSL Buys Novartis, Integrates It Successfully
CSL Limited has closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million. The combined business will create the second largest influenza vaccine business in...